Primary Site >> Liver Cancer

Gene >> IL2

  • 1986
  • 1987
  • 1988
  • 1989
  • 1990
  • 1991
  • 1992
  • 1993
  • 1994
  • 1995
  • 1997
  • 1998
  • 2001
  • 2002
  • 2003
  • 2005
  • 2007
  • 2010
  • 2011
  • 2013
  • 2014
  • 2015
  • 2016
  • 2017
  • 2018
Ref: Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells.
PMID: 2425926
Ref: Induction of lymphokine-activated killer cells in strain 2 guinea pigs with human interleukin-2.
PMID: 3489527
Ref: Interleukin 2 and lymphokine-activated killer cells in the treatment of childhood primary hepatocellular carcinoma--a preliminary report.
PMID: 3040030
Ref: Long-term influence of adjuvant therapy on natural killer cell activity in breast cancer.
PMID: 2460239
Ref: Immunotherapy of hepatocellular carcinoma with autologous lymphokine-activated killer cells and/or recombinant interleukin-2.
PMID: 2838488
Ref: Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
PMID: 3257715
Ref: Adoptive immunotherapy administered via the hepatic artery and intralesional interleukin-2 in hepatocellular carcinoma.
PMID: 2475251
Ref: Defective function of lymphokine-activated killer cells and natural killer cells in patients with hepatocellular carcinoma.
PMID: 2537790
Ref: Circulating LAK-1 cells and autologous mixed lymphocyte reaction in patients with hepatocellular carcinoma.
PMID: 2539011
Ref: Intratumoral echo-guided injection of interleukin-2 and lymphokine-activated killer cells in hepatocellular carcinoma.
PMID: 2559885
Ref: Unimpaired ability to generate adherent lymphokine-activated killer (A-LAK) cells in patients with primary or metastatic liver tumors.
PMID: 2624925
Ref: [Experimental and clinical study of adoptive immunotherapy combined with preadministration of OK-432: a method to augment the therapeutic effect].
PMID: 2786379
Ref: Lymphokine-activated killer cell activity in patients with primary and metastatic malignant liver tumors.
PMID: 2787271
Ref: Lymphokine-activated killer cell induction in tumor-infiltrating leukocytes from colon cancer patients.
PMID: 2804913
Ref: Defective immunological functions associated with abnormal lymphokine-activated killer activity in patients with hepatocellular carcinoma.
PMID: 1966592
Ref: Functional and phenotypic characteristics of recombinant interleukin-2 or T-cell growth factor-activated splenic lymphoid cells from patients with gastric or hepatocellular carcinoma.
PMID: 2167147
Ref: Antitumour effect of intratumoral injection of human recombinant interleukin-2 in patients with hepatocellular carcinoma: a preliminary report.
PMID: 2177345
Ref: [Significance of reduction surgery for stage IV hepatocellular carcinoma (HCC) and postoperative immunochemotherapy for extension of survival period].
PMID: 1658592
Ref: Crescentic IgA glomerulonephritis following interleukin-2 therapy for hepatocellular carcinoma of the liver.
PMID: 1668057
Ref: Effective immunotherapy with local low doses of interleukin-2.
PMID: 1810439
Ref: Augmentation of antitumor effect on syngeneic murine solid tumors by an interleukin 2 slow delivery system, the IL-2 mini-pellet.
PMID: 1854589
Ref: [Treatment of advanced liver cancer by autologous and/or homologous LAK cells combined with human natural LL-2].
PMID: 1879294
Ref: [LAK cell adoptive immunotherapy and its problems].
PMID: 1944194
Ref: Induction of allogeneic tumour- and lymphokine-activated lymphocytes against hepatocellular carcinoma.
PMID: 1315167
Ref: Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.
PMID: 8023699
Ref: Postoperative chemoimmunotherapy for the treatment of liver cancer.
PMID: 8210915
Ref: Immunological responses against an autologous human hepatocellular carcinoma cell line.
PMID: 8280838
Ref: Short-duration in vitro interleukin-2-activated mononuclear cells for advanced cancer. A Hong Kong biotherapy pilot study trial.
PMID: 8387882
Ref: Interleukin-2 in cancer treatment: disappointing or (still) promising? A review.
PMID: 8439974
Ref: [Induction of anti-cancer cells and systemic immune response in hepatocellular carcinoma by OK-432].
PMID: 7944416
Ref: Induction by OK-432 of lymphokine activated killer precursor cells in hepatocellular carcinoma.
PMID: 7959572
Ref: Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells.
PMID: 8033100
Ref: Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine neoplasms induce tumor-specific immune responses that prolong the lives of tumor-bearing mice.
PMID: 8528961
Ref: Efficacy and tolerability of cancer neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin - a progress report of 200 patients with advanced solid neoplasms.
PMID: 21597854
Ref: Intralesional sonographically guided injections of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: a pilot study.
PMID: 9087388
Ref: The tumor-bearing state induces augmented responses of organ-associated lymphocytes to high-dose interleukin-2 therapy in mice.
PMID: 9390196
Ref: In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2.
PMID: 9449371
Ref: Cytolytic activity of peripheral blood blast cells from patients with acute myeloid leukemia.
PMID: 9477127
Ref: Patterns of hepatic and splenic colonization by an attenuated strain of Salmonella typhimurium containing the gene for human interleukin-2: a novel anti-tumor agent.
PMID: 10851445
Ref: [Clinical evaluation of intermittent hepatic arterial infusion therapy for metastatic liver tumor of gastric and colorectal cancer].
PMID: 9703838
Ref: [Retroviral-mediated transcriptional regulatory elements of alpha-fetoprotein gene directed specific expression of interleukin-2 in murine hepatoma].
PMID: 11717988
Ref: Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer.
PMID: 11591892
Ref: Effects of cryopreservation and phenylacetate on biological characters of adherent LAK cells from patients with hepatocellular carcinoma.
PMID: 11925598
Ref: [Changes of immune function in liver cirrhosis patients after splenectomy combined with resection of hepatocellular carcinoma].
PMID: 11955389
Ref: Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo.
PMID: 12046071
Ref: Locoregional immunochemotherapy in hepatocellular carcinoma.
PMID: 12143214
Ref: [Immunoprotective effect of IL-2 and B7-1 gene co-transfected liver cancer vaccines on hepatocarcinogenesis in mice].
PMID: 12502440
Ref: Prevention of hepatocellular carcinoma in mice by IL-2 and B7-1 genes co-transfected liver cancer cell vaccines.
PMID: 14562374
Ref: Effects of splenectomy in patients with cirrhosis undergoing hepatic resection for hepatocellular carcinoma.
PMID: 14606076
Ref: Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C.
PMID: 16344072
Ref: Treatment of antibody-mediated rejection with high-dose immunoglobulins in ABO-incompatible liver transplant recipient.
PMID: 17263788
Ref: Generation of cellular immune responses to HCV NS5 protein through in vivo activation of dendritic cells.
PMID: 20002303
Ref: A new membrane re-anchored protein originating from GPC3 against hepatoma cells HepG2.
PMID: 21904776
Ref: Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma.
PMID: 23223899
Ref: T cells redirected to interleukin-13Ralpha2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Ralpha1.
PMID: 24841514
Ref: Kanglaite stimulates anticancer immune responses and inhibits HepG2 cell transplantationinduced tumor growth.
PMID: 25119060
Ref: Identification and functional characterization of a novel fungal immunomodulatory protein from Postia placenta.
PMID: 25662032
Ref: Characterization of solid tumors induced by polycyclic aromatic hydrocarbons in mice.
PMID: 25913077
Ref: Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
PMID: 27197065
Ref: Identification of Optimal Insertion Site in Recombinant Newcastle Disease Virus (rNDV) Vector Expressing Foreign Gene to Enhance Its Anti-Tumor Effect.
PMID: 27736965
Ref: Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.
PMID: 27965307
Ref: Tumor-Derived alpha-Fetoprotein Directly Drives Human Natural Killer-Cell Activation and Subsequent Cell Death.
PMID: 28468916
Ref: CpG oligonucleotides increase HBV-specific cytokine responses in whole blood and enhance cytokine release assay sensitivity.
PMID: 28739303
Ref: Genetically engineered recombinant adenovirus expressing interleukin2 for hepatocellular carcinoma therapy.
PMID: 29115604